{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:23:12Z","timestamp":1760908992602,"version":"3.40.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Egyptian National Cancer Institute"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jnci.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T09:04:15Z","timestamp":1462007055000},"page":"101-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-5964","authenticated-orcid":false,"given":"Mohamed W.","family":"Hegazy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7298-6150","authenticated-orcid":false,"given":"Rana I.","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed F.","family":"Al Otaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"1","key":"10.1016\/j.jnci.2016.04.001_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jnci.2016.04.001_b0010","doi-asserted-by":"crossref","first-page":"437971","DOI":"10.1155\/2014\/437971","article-title":"Cancer incidence in Egypt: results of the national population-based cancer registry program","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.jnci.2016.04.001_b0015","unstructured":"KFSH&RC, Tumor Registry Annual Report, <http:\/\/www.kfshrc.edu.sa\/oncology\/2012_Tumor_Registry_Annual_Report.pdf>; 2012 [accessed 19.06.15]."},{"key":"10.1016\/j.jnci.2016.04.001_b0020","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0030","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation therapy oncology group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0035","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92\u201302: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0040","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.ijrobp.2009.03.033","article-title":"Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases","volume":"76","author":"Zhang","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl. 1","key":"10.1016\/j.jnci.2016.04.001_b0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/0284186X.2011.562536","article-title":"Hypofractionation for radiotherapy of prostate cancer using a low alpha\/beta ratio possible reasons for concerns? an example of five dimensional radiotherapy","volume":"50","author":"Lennernas","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0050","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha\/beta Z 1.4 (0.9\u20132.2)Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jnci.2016.04.001_b0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jnci.2016.04.001_b0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semradonc.2008.04.002","article-title":"Clinical experience shows that catastrophic late effects associated with ablative fractionation can be avoided by technological innovation","volume":"18","author":"Kavanagh","year":"2008","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"10.1016\/j.jnci.2016.04.001_b0065","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jnci.2016.04.001_b0070","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0360-3016(03)00739-9","article-title":"Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience","volume":"57","author":"Sylvester","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.jnci.2016.04.001_b0075","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jnci.2016.04.001_b0080","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy\u2019s 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jnci.2016.04.001_b0085","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jnci.2016.04.001_b0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.2011.1333","article-title":"Prediction of erectile function following treatment for prostate cancer","volume":"306","author":"Alemozaffar","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jnci.2016.04.001_b0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3857\/roj.2014.32.3.187","article-title":"Treatment outcome of localized prostate cancer by 70Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon","volume":"32","author":"Kim","year":"2014","journal-title":"Radiat Oncol J"},{"issue":"5","key":"10.1016\/j.jnci.2016.04.001_b0100","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ijrobp.2007.01.067","article-title":"Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer. Cleveland clinical experience","volume":"68","author":"Kupelian","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.jnci.2016.04.001_b0105","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S1470-2045(08)70236-5","article-title":"Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial","volume":"9","author":"Denham","year":"2008","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jnci.2016.04.001_b0110","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jnci.2016.04.001_b0115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clon.2010.01.005","article-title":"Intensity modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study","volume":"22","author":"Guerrero Urbano","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.jnci.2016.04.001_b0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomized controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomized non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jnci.2016.04.001_b0130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jrr\/rru086","article-title":"Whole-pelvic volumetric-modulated arc therapy for high-risk prostate cancer: treatment planning and acute toxicity","volume":"56","author":"Ishii","year":"2015","journal-title":"J Radiat Res"},{"issue":"3","key":"10.1016\/j.jnci.2016.04.001_b0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1748-717X-3-15","article-title":"High-dose intensity modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients","volume":"21","author":"Lips","year":"2008","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.jnci.2016.04.001_b0145","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited \u2013 an analysis of clinical results from 14,168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jnci.2016.04.001_b0150","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/860639","article-title":"Significance of image guidance to clinical outcomes for localized prostate cancer","volume":"2014","author":"Zhong","year":"2014","journal-title":"Biomed Res Int"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036216300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036216300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T09:40:01Z","timestamp":1558604401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1110036216300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1110036216300073"],"URL":"https:\/\/doi.org\/10.1016\/j.jnci.2016.04.001","relation":{},"ISSN":["1110-0362"],"issn-type":[{"type":"print","value":"1110-0362"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience","name":"articletitle","label":"Article Title"},{"value":"Journal of the Egyptian National Cancer Institute","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnci.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}